TEVA

Teva reported its 11th consecutive quarter of growth, with a 3% increase in revenue to $4.5 billion in Q3 2025. Key products such as Austedo, UZEDY, and AJOVY showed strong sales growth, contributing to the robust performance. The company's net debt to EBITDA ratio improved, dropping below 3x for the first time since 2016, indicating enhanced financial stability.

Teva's Q3 2025 earnings exceeded expectations, with adjusted EPS of $0.78, surpassing the consensus of $0.67. Revenue also exceeded expectations, with Teva reporting $4.48 billion, higher than the estimated $4.34 billion. This marks the first earnings beat for Teva in 2025.

Teva raised its full-year revenue guidance to $16.8-$17.0 billion, narrowing the range from a prior high end of $17.2 billion. The company also boosted adjusted EPS guidance to $2.55-$2.65, up from $2.50-$2.65 previously. This reflects confidence in the company's continued growth and profitability.

Teva's focus on innovative products and cost-saving measures is paying off, with the company's transformation program achieving $70 million in savings in 2025 and a target of $700 million by 2027. The company's pipeline and partnerships in biosimilars and other therapeutic areas are also promising.

The positive earnings report and guidance raise have boosted investor confidence, leading to a surge in the stock price. Analysts are increasingly optimistic about Teva's prospects, with a consensus rating of "Buy/Strong Buy" and target prices hovering around $25-$26.